NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CAR §1.821 - §1.825 for the following reasons(s):

[X] 1. This application clearly fails to comply with the requirements of 37 CAR §1.821 - §1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990, and at 55 FR 18230, May 1, 1990.

[X] 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CAR §1.821(c).

[X] 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CAR §1.821(e).

[ ] 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 CAR §1.822 and/or §1.823, as indicated on the attached copy of the "Validation Report."

[ ] 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached "Validation Report." A substitute computer readable form must be submitted as required by 37 CAR §1.825(d).

[ ] 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CAR §1.821(e).

[ ] 7. Other: _____

APPLICANT MUST PROVIDE:

[X] An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."

[X] An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.

[X] A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CAR §1.821(e) or §1.821(f) or §1.821(g) or §1.825(b) or §1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

For Rules Interpretation, call (571)272-0951
For Patentin Software help, call (866)217-9197 or (703)-305-3028/308-6845

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE.

PATENT APPLICATION
U.S. Appln. No. 10/554,625
Intl. Appln. No. PCT/US04/12510
Attorney Docket No. PP020407.0004

I hereby certify that this paper (and all documents referred to herein) is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Mail Stop Missing Parts, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the below identified date.

June 3, 2009
Date

Kara Shure

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: O'HAGAN *et al.*	
U.S. Appln. No.: 10/554,625	Confirmation No.: 7269
Intl. Appln. No.: PCT/US2004/012510	Group Art Unit: 1648
I.A. Filing Date: 23 April 2004	Examiner: Zachariah Lucas
Title: COMPOSITIONS COMPRISING CATIONIC MICROPARTICLES AND HCV E1E2 DNA AND METHODS OF USE THEREOF	

TRANSMITTAL OF SEQUENCE LISTING IN COMPUTER READABLE FORM IN COMPLIANCE WITH 37 C.F.R. §§1.821-1.825 AND STATEMENTS UNDER 37 C.F.R. §§1.821 (f) AND (g)

Mail Stop Missing
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith is a copy of the "Sequence Listing" in paper form (sheets 1/6 through 6/6, comprising SEQ ID NOs: 1-2) for the above-identified application as required by 37 C.F.R. § 1.821(c) and a copy of the "Sequence Listing" in computer readable form as required by 37 C.F.R. § 1.821(e). As required by 37 C.F.R. § 1.821(f), the undersigned states that the content of the "Sequence Listing" in paper form and the computer readable form of the "Sequence Listing" are the same and, as required by 37 C.F.R. §1.821(g), also states that the submission includes no new matter.

Applicant respectfully requests the content of the sequence listing provided on compact disc herewith be entered in its entirety into the application.

Respectfully submitted,

NOVARTIS VACCINES AND DIAGNOSTICS, INC.

Dated: 03 June 2009

By: _____
Helen Lee
Registration No. 39,270

Customer No. 27476
NOVARTIS VACCINES AND DIAGNOSTICS, INC.
Intellectual Property – X100B
P.O. Box 8097
Emeryville, CA 94662-8097
Tel (510) 923-2192
Fax (510) 655-3542